ReviewInflammopharmacology2025
Natural products and nutraceuticals in the management of chronic inflammatory diseases: efficacy, mechanisms, and comparative insights.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identification of Novel Anti-Inflammatory Peptides from JellyfishMarine drugs · 2026Article
- Dicranum scoparium extract modulates the NOX2/SOD2 axis and NF-κB signaling in a fibroblast-macrophage co-culture model.Molecular biology reports · 2026Article
- The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammatory diseases represent a significant global health burden, driving increased exploration of natural products and nutraceuticals as complementary or alternative therapeutic options. This review provides a comprehensive evaluation of the molecular and cellular mechanisms by which natural compounds modulate inflammatory pathways, focusing on their antioxidant, immunomodulatory, and anti-inflammatory effects distinct from conventional nonsteroidal anti-inflammatory drugs (NSAIDs). Drawing on evidence from recent clinical trials and preclinical animal studies, we examine their therapeutic potential across diverse inflammatory conditions including gastrointestinal disorders, rheumatic diseases, neuroinflammation, and inflammation-associated muscle dysfunction related to aging and injury. The article critically compares the efficacy and safety profiles of natural agents with established pharmacological therapies, emphasizing advantages and limitations supported by current data. Furthermore, regulatory considerations, challenges in standardization, and quality control issues surrounding natural products are discussed, alongside their integration into personalized treatment regimens. By highlighting gaps in knowledge and emerging avenues for research, such as discovery of novel bioactive compounds and improved clinical trial designs, this review aims to guide future investigations and clinical application. Overall, the synthesis offers valuable insights for researchers, clinicians, and policymakers seeking innovative and safe anti-inflammatory strategies grounded in natural product research.
Indexed as
Identifiers
40960578What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.